Effect of 35624® Alflorex® in Functional Gastrointestinal Disorders (FGIDs) in Children.

Open Label Clinical Trial on the Efficacy of a Probiotic Strain of Bifidobacterium Longum 35624 (Alflorex®) in Functional Gastrointestinal Disorders (GFRS) in Children 8 to 18 Years of Age.

The aim of this study is to evaluate the effect of supplementation with Bifidobacterium longum 35624® Alflorex® on frequency and severity of symptoms of abdominal pain using an adapted Irritable Bowel Symptom Severity Scoring System (IBS-SSS) to accurately reflect the pediatric population using the aid of the validated Numeric Pain Rating Scale (NRS-II) in children with Functional Gastrointestinal Disorders (FGIDs).

Study Overview

• Status: Completed
• Conditions: Functional Abdominal Pain; Functional Gastrointestinal Disorders
• Intervention / Treatment: Dietary supplement: Alflorex®

Detailed Description

This is an open label study to assess the safety and effectiveness of Bifidobacterium longum 35624® Alflorex® when consumed once daily by children with Functional Gastrointestinal Disorders (FGIDs). The 12-week intervention study will be conducted in 63 non-coeliac children aged 8 to 18 years old with an FGID who experience at least two episodes of abdominal pain per week. The study will consist of 5 visits over a 14 week period commencing with a screening visit. The second visit will be the baseline (start of intervention), followed by third (mid-intervention), fourth (end of treatment) and fifth (follow up) visit. Questionnaires will be administered from the second to the fifth visit. A blood sample will be taken before treatment to rule out coeliac disease.

• Study Type: Interventional
• Enrollment (Actual): 65
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Chile
  • Santiago, Chile
    • Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age 8-18 years
2. Any sex
3. ROME IV diagnostic criteria Pediatric functional digestive disorders: in children and adolescents. H2. Functional abdominal pain disorders H2a. Functional dyspepsia H2b. Irritable bowel syndrome H2d. Functional abdominal pain not otherwise specified H3. Functional defecation disorders H3a. Functional constipation H3b. Non-retentive fecal incontinence Meet the criteria during the last three months with the onset symptoms for at least six months before diagnosis
4. IBS rated moderate to severe according to GSRS-IBS score (Spanish / LA)
5. At least two episodes of abdominal pain per week
6. No consumption of probiotics at least two weeks before baseline measurements (but preferably four weeks);
7. Dad, Mom, or Guardian able to understand the protocol;
8. Be willing to maintain stable dietary habits throughout the study period;
9. Be able to communicate well with the Investigator, to understand and comply with the requirements of the study and be judged suitable for the study in the opinion of the Investigator;
10. Signature of Informed Consent.

Exclusion Criteria:

1. Children with systemic, organic or metabolic diseases, immunosuppression, different from IBS
2. Previous major abdominal surgery;
3. Consumption of proton pump inhibitors, H2 antagonists;
4. Consumption of probiotics in the two weeks before baseline measurements;
5. Are less than 8 or older than 18 years of age at the time of consent;
6. Subject who has been on antibiotics during the past 3 months;
7. Subjects who have not had at least two episodes of abdominal pain per week;
8. Subject with a malignant disease or any concomitant end-state organ disease and/or laboratory abnormalities considered by Investigators to be risky or that could interfere with data collection;
9. Subject who are coeliac or lactose intolerant;
10. Known allergy to any of the components of the test product;
11. Participation in a clinical study with an investigational product within 60 days before screening, or plans to participate in another study during the study period;
12. Subject has a history of non-compliance;
13. Use of dietary supplements or other fermented foods that contain live bacteria.
14. Pregnant or lactating females.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Probiotic; Alflorex® The participants consume one probiotic capsule a day for 12 weeks.	Dietary supplement: Alflorex®; Each probiotic capsule contains 1 x 10^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in abdominal pain assessed by the Numeric Rating Scale for pain	The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain which goes from 0 (no pain) to 10 (worst pain)	Change from baseline, assessed at 6 and 12 weeks of supplement intake
Change in IBS symptom severity assessed by an adapted Irritable Bowel Symptom Severity Scoring System (IBS-SSS)	The IBS-SSS measures symptom severity in IBS patients and is a reliable and validated questionnaire taking into account the composite score of abdominal pain, number of days with abdominal pain, bloating/distention, satisfaction with bowel habits and IBS-related quality of life. For this study, an adapted version was used in conjunction with the NRS-11 pain scale for the purposes of accurately capturing the response of a pediatric population. The NRS-11 pain scale goes from 0-10 with 0 indicating "no pain" and 10 indicating "very severe pain."	Change from baseline, assessed at 6 and 12 weeks of supplement intake

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in quality of life assessed by the Irritable Bowel Syndrome-Quality of Life questionnaire	The IBS-QOL scoring is from 0 to 100, with higher scores indicating better IBS specific quality of life	Change from baseline, assessed at 6 and 12 weeks of supplement intake
Change in stool consistency assessed using the Bristol Stool Form Scale	The Bristol Stool Form Scale classifies stool according to shape and consistency and assigns a sample a number from 1-7 depending on its characteristics, corresponding to constipation normal or diarrhea.	Change from baseline, assessed at 6 and 12 weeks of supplement intake
Change in stool frequency	Assessed from patient diaries	Change from baseline, assessed at 6 and 12 weeks of supplement intake
Change in days absent from school	Assess from patient diaries	Change from baseline, assessed at 6 and 12 weeks of supplement intake

Collaborators and Investigators

• Sponsor: PrecisionBiotics Group Ltd.
• Collaborators: Instituto de Nutrición y Tecnología de los Alimentos
• Investigators: Study Director: Eileen Murphy, PhD, PrecisionBiotics Group Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 6, 2021
• Primary Completion (Actual): March 4, 2023
• Study Completion (Actual): April 4, 2023

Study Registration Dates

• First Submitted: June 4, 2021
• First Submitted That Met QC Criteria: June 9, 2021
• First Posted (Actual): June 10, 2021

Study Record Updates

• Last Update Posted (Actual): September 8, 2023
• Last Update Submitted That Met QC Criteria: September 5, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Probiotic; Food supplement; Bifidobacterium longum 35624®; Alflorex®
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Signs and Symptoms, Digestive; Abdominal Pain; Gastrointestinal Diseases; Digestive System Diseases
• Other Study ID Numbers: PBCT002A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No